logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > 177Lu-PSMA-617 for metastatic castrationresistant prostate cancer – third line

< Back

177Lu-PSMA-617 for metastatic castrationresistant prostate cancer – third line

Drugs

Cancer and Palliative Care

July 2020


177Lu-PSMA-617 is in clinical development for patients with metastatic castrationresistant prostate cancer (mCRPC) who have been previously treated with androgen receptor-directed therapy (ARDT) and a taxane-based chemotherapy. Prostate cancer is a cancer of the prostate gland and mCRPC is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. The symptoms of prostate cancer may vary depending on the stage but can include pain, tiredness, and problems emptying the bladder and the bowels. Treatment options for mCRPC are currently limited in patients that have progressed following treatment with ARDT and a taxane-based chemotherapy.

177Lu-PSMA-617 delivered via intravenous infusion. It works by releasing an energetic beta particle to precisely deliver cell-killing radiation to the site of disease to kill cancer cells. Earlier studies indicate that 177Lu-PSMA-617 may demonstrate clinical benefit in patients with mCRPC in the third-line setting, where patients have no clear standard of care, having exhausted all key treatment options. If licensed, 177LuPSMA-617 will provide a treatment option for patients in this setting.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts